Senzime signs Nordic distribution agreement with Vingmed Holding A/S

Press release: Uppsala, May 6, 2019. Senzime AB (publ) today announces that it has signed an exclusive distribution agreement with Vingmed Holding A/S for the commercialization of TetraGraph in Sweden, Denmark, Norway and Finland.

The Vingmed Group consists of 4 direct sales organisations: Vingmed AS (Norway), Vingmed AB (Sweden), Vingmed ViCare A/S (Denmark), Vingmed Oy (Finland) and is one of the largest companies in the Nordic countries for distribution and services of high quality medical technical products. Anesthesia is one of their focus areas and high level of innovation and continuity are factors of great importance when incorporating new products. In Denmark and Norway they are the distributor of Philips IntelliVue patient monitors, a great match since Senzime will launch the communication protocol between TetraGraph and IntelliVue in the end of the second quarter this year.  

Pia Renaudin, Senzimes CEO, commented:” The agreement with Vingmed will make it possible for us to meet the increasing interest in Sweden and expand our offer to the other Nordic countries. This agreement is very important for us and with Vingmeds extensive experience and great reputation we have found a strong partner. Together with our distributors we are building the foundation for growth in the field of Neuromuscular monitoring”.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                                 

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com         

TO THE EDITORS

About Senzime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se, is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on May 6, 2019 15:00 

Tags:

About Us

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com

Subscribe

Media

Media

Documents & Links